A Phase 2 interventional study of brentuximab vedotin and brentuximab vedotin in Acute Lymphoid Leukemia, Acute Myeloid Leukemia and Anemia, Refractory, With Excess of Blasts, sponsored by Seagen Inc.. Completed at 29 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2016-03-04.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Pfizer — 1 open to participants now, 2 under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Pfizer.
Among the 11 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Pfizer, this one is one of 2 that started in 2011, is one of 3 in phase 2, and was the 2nd registered.
2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →1 of the 11 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Pfizer is open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in Austria, Belgium, Czechia and 12 more countries
Ages 1–17
By country, each count listing its studies:
Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 92 across the 6 interventional studies, 32 across the 5 observational. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
Drug: brentuximab vedotin
Brentuximab vedotin 2.4 mg/kg every 3 weeks by IV infusion
Drug: brentuximab vedotin
Brentuximab vedotin 1.2 mg/kg weekly, 3 out of 4 weeks, by IV infusion
Drug: brentuximab vedotin
1.8 mg/kg every 3 weeks by intravenous (IV) infusion
Also known as: Adcetris; SGN-35
2.4 mg/kg every 3 weeks by intravenous (IV) infusion
Also known as: Adcetris; SGN-35
1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
Also known as: Adcetris; SGN-35
Objective Response Rate (ORR) by Investigator
Percentage of participants who achieved a best response of complete response/remission (CR), CR without hematologic recovery (CRi; leukemia only), or partial remission (PR) per the applicable response criteria. Response criteria for solid tumors (by radiographic tumor imaging) per Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 (Eisenhauer 2009); response criteria for leukemia (by peripheral blood and bone marrow aspirate or biopsy) per International Working Group (Cheson 2003).
Time frame: Up to approximately 3 years
Complete Remission (CR) Rate by Investigator
Percentage of participants who achieved a best response of CR per the applicable response criteria. Response criteria for solid tumors (by radiographic tumor imaging) per Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 (Eisenhauer 2009); response criteria for leukemia (by peripheral blood and bone marrow aspirate or biopsy) per International Working Group (Cheson 2003).
Time frame: Up to approximately 3 years
Duration of Objective Response by Kaplan-Meier Analysis
Duration of objective response (CR \[+CRi; leukemia\] + PR), defined as time of initial response until disease progression or death. Response criteria for solid tumors (by radiographic tumor imaging) per Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 (Eisenhauer 2009); response criteria for leukemia (by peripheral blood and bone marrow aspirate or biopsy) per International Working Group (Cheson 2003).
Time frame: Up to approximately 2 years
Duration of Complete Response by Kaplan-Meier Analysis
Duration of CR, defined as time of initial response until disease progression or death. Response criteria for solid tumors (by radiographic tumor imaging) per Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 (Eisenhauer 2009); response criteria for leukemia (by peripheral blood and bone marrow aspirate or biopsy) per International Working Group (Cheson 2003).
Time frame: Up to approximately 2 years
Progression-Free Survival by Kaplan-Meier Analysis
Progression-free survival, defined as time from start of study treatment to disease progression per investigator or death due to any cause
Time frame: Up to approximately 2 years
Adverse Events by Severity, Seriousness, and Relationship to Treatment
Counts of participants who had treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on Study SGN35-013). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life-threatening/disabling, 5=fatal). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.
Time frame: Up to approximately 3 years
Laboratory Abnormalities >/= Grade 3
Counts of study participants with post-baseline laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 4.03. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category
Time frame: Up to approximately 3 years
Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Concentration at End of Infusion (Ceoi)
Time frame: Up to approximately 3 years
Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Trough Concentration (Ctrough)
Time frame: Up to approximately 3 years
Maximum Concentration (Cmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE)
Time frame: Up to approximately 3 years
Brentuximab Vedotin Monomethyl Auristatin E (MMAE) Trough Concentration (Ctrough)
Time frame: Up to approximately 3 years
Incidence of Anti-therapeutic Antibodies (ATA)
Counts of participants with post-baseline anti-brentuximab vedotin antibodies. Persistently positive is defined as confirmed ATA in more than 2 post-baseline samples and transiently positive is defined as confirmed ATA in 1 or 2 post-baseline samples.
Time frame: Up to approximately 3 years
Oct 2011 - Dec 2014
| Milestone | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week |
|---|---|---|---|
| Started | 46 | 28 | 9 |
| Completed | 28 | 20 | 7 |
| Not completed | 18 | 8 | 2 |
| Withdrew: Death | 15 | 6 | 2 |
| Withdrew: Study stopped by sponsor | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
Percentage of participants who achieved a best response of complete response/remission (CR), CR without hematologic recovery (CRi; leukemia only), or partial remission (PR) per the applicable response criteria. Response criteria for solid tumors (by radiographic tumor imaging) per Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 (Eisenhauer 2009); response criteria for leukemia (by peripheral blood and bone marrow aspirate or biopsy) per International Working Group (Cheson 2003).
| percentage of participants | Solid Tumors | Leukemia |
|---|---|---|
| Objective Response Rate (ORR) by Investigator | 12 (4.9 to 22.9) | 14 (1.8 to 42.8) |
Percentage of participants who achieved a best response of CR per the applicable response criteria. Response criteria for solid tumors (by radiographic tumor imaging) per Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 (Eisenhauer 2009); response criteria for leukemia (by peripheral blood and bone marrow aspirate or biopsy) per International Working Group (Cheson 2003).
| percentage of participants | Solid Tumors | Leukemia |
|---|---|---|
| Complete Remission (CR) Rate by Investigator | 2 (0.0 to 9.1) | 0 (0 to 23.2) |
Duration of objective response (CR \[+CRi; leukemia\] + PR), defined as time of initial response until disease progression or death. Response criteria for solid tumors (by radiographic tumor imaging) per Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 (Eisenhauer 2009); response criteria for leukemia (by peripheral blood and bone marrow aspirate or biopsy) per International Working Group (Cheson 2003).
| months | Solid Tumors | Leukemia |
|---|---|---|
| Duration of Objective Response by Kaplan-Meier Analysis | 2.9 (1.5 to 23.5) | 2.1 (1.0 to 3.1) |
Duration of CR, defined as time of initial response until disease progression or death. Response criteria for solid tumors (by radiographic tumor imaging) per Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 (Eisenhauer 2009); response criteria for leukemia (by peripheral blood and bone marrow aspirate or biopsy) per International Working Group (Cheson 2003).
| months | Solid Tumors | Leukemia |
|---|---|---|
| Duration of Complete Response by Kaplan-Meier Analysis | 22.3 (22.3 to 22.3) | — |
Progression-free survival, defined as time from start of study treatment to disease progression per investigator or death due to any cause
| months | Solid Tumors | Leukemia |
|---|---|---|
| Progression-Free Survival by Kaplan-Meier Analysis | 2.1 (1.3 to 2.8) | 0.7 (0.7 to 1.3) |
Counts of participants who had treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on Study SGN35-013). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life-threatening/disabling, 5=fatal). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.
| participants | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week |
|---|---|---|---|
| Any TEAE | 45 | 28 | 9 |
| TEAE related to study drug | 31 | 24 | 5 |
| TEAE with severity grade >/=3 | 31 | 18 | 7 |
| Discontinued treatment due to adverse event | 5 | 2 | 2 |
| Serious adverse event | 24 | 13 | 5 |
| Serious adverse event related to study drug | 5 | 6 | 2 |
| Deaths (within 30 days of last dose) | 10 | 6 | 2 |
Counts of study participants with post-baseline laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 4.03. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category
| participants | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week |
|---|---|---|---|
| Any >/= Grade 3 laboratory abnormality | 24 | 12 | 9 |
| Alanine aminotransferase high | 0 | 1 | 1 |
| Albumin low | 2 | 3 | 0 |
| Alkaline phosphatase high | 0 | 1 | 0 |
| Aspartate aminotransferase high | 0 | 1 | 0 |
| Bilirubin high | 0 | 1 | 0 |
| Calcium low | 1 | 1 | 0 |
| Glucose high | 2 | 1 | 0 |
| Glucose low | 1 | 0 | 0 |
| Sodium low | 4 | 2 | 0 |
| Urate high | 2 | 0 | 0 |
| Prothrombin INR high | 0 | 0 | 1 |
| Absolute neutrophil count low | 6 | 2 | 5 |
| Hemoglobin low | 4 | 0 | 3 |
| Leukocytes high | 0 | 1 | 1 |
| Leukocytes low | 4 | 0 | 4 |
| Lymphocytes high | 1 | 2 | 0 |
| Lymphocytes low | 9 | 3 | 1 |
| Neutrophils low | 6 | 3 | 7 |
| Platelets low | 4 | 4 | 7 |
| ug/mL | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week |
|---|---|---|---|
| Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Concentration at End of Infusion (Ceoi) | 40 ± 26 | 54 ± 28 | 25 ± 23 |
| ug/mL | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week |
|---|---|---|---|
| Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Trough Concentration (Ctrough) | 0.36 ± 180 | 0.55 ± 210 | 1.5 ± 48 |
| ng/mL | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week |
|---|---|---|---|
| Maximum Concentration (Cmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE) | 4.0 ± 78 | 6.2 ± 71 | 2.6 ± 83 |
| ng/mL | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week |
|---|---|---|---|
| Brentuximab Vedotin Monomethyl Auristatin E (MMAE) Trough Concentration (Ctrough) | 0.22 ± 92 | 0.35 ± 82 | 1.5 ± 65 |
Counts of participants with post-baseline anti-brentuximab vedotin antibodies. Persistently positive is defined as confirmed ATA in more than 2 post-baseline samples and transiently positive is defined as confirmed ATA in 1 or 2 post-baseline samples.
| participants | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week |
|---|---|---|---|
| Baseline (BL) negative | 33 | 21 | 8 |
| BL negative, negative post-BL | 14 | 14 | 8 |
| BL negative, transiently positive post-BL | 18 | 6 | 0 |
| BL negative, persistently positive post-BL | 1 | 1 | 0 |
| BL positive | 3 | 2 | 0 |
| BL positive, negative post-BL | 1 | 0 | 0 |
| BL positive, transiently positive post-BL | 2 | 1 | 0 |
| BL positive, persistently positive post-BL | 0 | 1 | 0 |
Collected over Up to approximately 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BV 1.8 mg/kg Q3Week | — | 24/46 (52.2%) | 42/46 (91.3%) |
| BV 2.4 mg/kg Q3Week | — | 13/28 (46.4%) | 28/28 (100%) |
| BV 1.2 mg/kg Q1Week | — | 5/9 (55.6%) | 8/9 (88.9%) |
| Event | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/46 | 0/28 | 1/9 |
| Atrial fibrillationCardiac disorders | 1/46 | 0/28 | 1/9 |
| DiarrheaGastrointestinal disorders | 1/46 | 1/28 | 1/9 |
| StomatitisGastrointestinal disorders | 0/46 | 0/28 | 1/9 |
| PyrexiaGeneral disorders | 1/46 | 1/28 | 1/9 |
| Hepatic failureHepatobiliary disorders | 0/46 | 0/28 | 1/9 |
| Bacterial sepsisInfections and infestations | 0/46 | 0/28 | 1/9 |
| PneumoniaInfections and infestations | 2/46 | 1/28 | 1/9 |
| DehydrationMetabolism and nutrition disorders | 2/46 | 0/28 | 1/9 |
| Acute myeloid leukemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/46 | 2/28 | 1/9 |
| Event | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week |
|---|---|---|---|
| FatigueGeneral disorders | 26/46 | 10/28 | 3/9 |
| AnemiaBlood and lymphatic system disorders | 6/46 | 1/28 | 4/9 |
| NauseaGastrointestinal disorders | 13/46 | 11/28 | 0/9 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/46 | 0/28 | 3/9 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 8/46 | 6/28 | 3/9 |
| Decreased appetiteMetabolism and nutrition disorders | 11/46 | 9/28 | 2/9 |
| DiarrheaGastrointestinal disorders | 14/46 | 5/28 | 2/9 |
| ConstipationGastrointestinal disorders | 9/46 | 7/28 | 1/9 |
| VomitingGastrointestinal disorders | 11/46 | 7/28 | 0/9 |
| Peripheral sensory neuropathyNervous system disorders | 8/46 | 7/28 | 1/9 |
All participants who received treatment. One additional patient enrolled, but withdrew prior to treatment group assignment.
| Age, Continuous(years) | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week | Total |
|---|---|---|---|---|
| Median | 64 (24 to 85) | 64 (18 to 85) | 76 (33 to 87) | 65 (18 to 87) |
| Sex: Female, Male(Participants) | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week | Total |
|---|---|---|---|---|
| Female | 21 | 12 | 4 | 37 |
| Male | 25 | 16 | 5 | 46 |
| Ethnicity (NIH/OMB)(Participants) | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 0 | 4 |
| Not Hispanic or Latino | 44 | 26 | 9 | 79 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 0 | 2 |
| White | 42 | 25 | 9 | 76 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| Region of Enrollment(participants) | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week | Total |
|---|---|---|---|---|
| United States | 46 | 28 | 9 | 83 |
| Eastern Cooperative Oncology Group Performance Status(participants) | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week | Total |
|---|---|---|---|---|
| 0 | 13 | 5 | 1 | 19 |
| 1 | 20 | 15 | 5 | 40 |
| 2 | 0 | 0 | 1 | 1 |
| 3-5 | 0 | 0 | 0 | 0 |
| Missing | 13 | 8 | 2 | 23 |
| Height(centimeters (cm)) | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week | Total |
|---|---|---|---|---|
| Median | 170.2 (142 to 188) | 171.9 (150 to 186) | 167.6 (144 to 180) | 170.2 (142 to 188) |
| Weight(kilograms (kg)) | BV 1.8 mg/kg Q3Week | BV 2.4 mg/kg Q3Week | BV 1.2 mg/kg Q1Week | Total |
|---|---|---|---|---|
| Median | 74.8 (46 to 109) | 75.1 (49 to 104) | 73.4 (45 to 137) | 74.8 (45 to 137) |
1 further baseline measures are reported on the registry.
The record gives a start of Oct 2011, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin
Precursor Cell Lymphoblastic Leukemia-Lymphoma →